Product Description
ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2). In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson's disease and progressive supranuclear palsy. (Sourced from: https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-first-human-dosing-arv-102-investigational)
Mechanisms of Action: LRRK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Arvinas
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Arvinas announced they will present P1 Parkinson's Disease results in 4Q26 for ARV-102
- Clinical Trial Start Expected - Arvinas announced they will initiate a P1 Progressive Supranuclear Palsy trial in 2H26 for ARV-102
- Clinical Outcomes Expected - Arvinas announced they will present P1 Parkinson's Disease results in 2H26 for ARV-102
Highest Development Phases
Phase 1: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|